CSIMarket
 


X4 Pharmaceuticals Inc  (XFOR)
Other Ticker:  
 

Cumulative X4 Pharmaceuticals Inc's Working Capital Ratio for Trailing Twelve Months Period

XFOR's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

XFOR Working Capital Ratio for Trailing Twelve Months Period

(Mar 31 2024)
I. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
III. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Growth 6.07 % -11.74 % 1.14 % 32.08 % 63.16 %
Y / Y Current Assets Growth -32.13 % 72.51 % 180.78 % 38.57 % 46.43 %
Working Capital Ratio for Trailing Twelve Months Period 5.59 6.16 5.23 4.16 4.05
Total Ranking # 368 # # 582 # 767 # 1076
Seq. Current Liabilities Growth -7.85 % 15.23 % 15.27 % -13.34 % -23.31 %
Seq. Current Assets Growth -40.94 % 0.15 % 50.32 % -23.67 % 50.12 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Mar 31 2024
On the trailing twelve months basis Due to decrease in Current Liabilities in the I. Quarter to $22 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period decreased to 5.59 below X4 Pharmaceuticals Inc average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 49 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than X4 Pharmaceuticals Inc. While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about XFOR
Working Capital Ratio XFOR in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 50
Sector # 279
S&P 500 # 579


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
12.08 6.6 3.73
(Jun 30 2020)   (Sep 30 2022)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Mar 31 2024, within Biotechnology & Pharmaceuticals Industry Working Capital Ratio for Trailing Twelve Months Period
Replimune Group Inc   15.36 
Relay Therapeutics Inc   15.19 
Genenta Science S p a   14.81 
Crispr Therapeutics Ag  14.56 
Achilles Therapeutics Plc  14.24 
Ikena Oncology Inc   14.21 
Molecular Partners Ag  13.88 
Krystal Biotech Inc   13.83 
Invivyd Inc   13.72 
Autolus Therapeutics Plc  13.67 
Protara Therapeutics Inc   13.66 
Kymera Therapeutics Inc   13.57 
Anavex Life Sciences Corp   13.27 
Iteos Therapeutics Inc   12.61 
Cabaletta Bio Inc   12.61 
Creative Medical Technology Holdings Inc   12.14 
Tarsus Pharmaceuticals Inc   10.95 
Cardiff Oncology inc   10.77 
Caribou Biosciences Inc   10.61 
Immunovant Inc   10.52 
Scholar Rock Holding Corp  10.45 
Jasper Therapeutics Inc   10.40 
Allogene Therapeutics Inc   10.33 
Monte Rosa Therapeutics Inc   10.18 
Century Therapeutics inc   10.10 
Springworks Therapeutics Inc   9.82 
Avrobio Inc   9.64 
Argenx se  9.60 
Elevation Oncology inc   9.59 
Ambrx Biopharma Inc   9.55 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com